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Abstract 
 
 
 
 
 
 
 
Photodynamic therapy is a modern treatment with applications in several medical 
specialties, which has been intensely studied in the last years. The main indications in 
dermatology are actinic keratosis, superficial basal cell carcinoma and Bowen's disease- 
common skin disorders in which photodynamic therapy proved its efficacy. At present, the 
use of photodynamic therapy for the treatment of other skin disorders is profoundly 
researched. Pain is the most common and redoubtable adverse effect of photodynamic 
therapy and it is the most important factor affecting the patient's adherence to treatment. The 
aim of this article is to look over the most recent medical studies regarding pain in PDT, 
with emphasis on the factors affecting the occurrence of pain and the most recent strategies 
for controlling photodynamic therapy- related pain.  
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Introduction 
Photodynamic therapy (PDT) is a modern 
treatment which has been used in several medical 
specialties in the last years, especially for the 
treatment of various cancers and infections, but 
also inflammatory disorders and photo-
rejuvenation. It involves the selective uptake of a 
photosensitizing agent by the targeted cell or 
tissue, light activation and cell destruction in the 
presence of oxygen (1, 2). 
 PDT was first described by Oscar Raab, a 
medical student from Munich who was studying 
the effect of acridine orange on the cultures of 
Paramecium caudatum. The student noticed that 
the cultures were destroyed when they were 
exposed to both acridine and light but not when 
they were exposed to acridine alone. Based on this 
discovery, his professor dr. Von Tappeiner, further 
researched the phenomenon and later called it 
photodynamic action. The therapy was extensively 
studied in the last hundred years in an attempt to 
discover better sensitizers, light sources or 
techniques. The discovery of photosensitizers like 
hematoporphyrin (Meyer Betz, 1913), 
hematoporphyrin derivative (Schwartz, 1955) and 
5-aminolevulinic acid (Kennedy and Pottier, 1990) 
are key moments in the history of PDT (3-5).  
 PDT requires the concomitant presence of a 
photosensitizer, light with an adequate wavelength 
and oxygen (2). Most photosensitizers have a 
tetrapyrrole structure. They can be classified as 
porphyrins and non-porphyrins and are 
administered systemically or topically. A 
photosensitizer must be selectively taken by the 
targeted tissue, absorb light of an appropriate 
wavelength and destroy specific cells or tissues. 
The most commonly used photosensitizers in 
dermatology are 5-aminolevulinic acid (ALA) and 
its ester, methyl aminolevulinate (MAL) (3, 6).  
Several light sources can be used in PDT, 
including non-coherent light sources, light-
emitting diodes and lasers. Natural light has also 
been used with some good results. The wavelength 
is also important. Tissue penetration is best 
between 600 and 1200 nm. However, oxygen 
cannot be generated by wavelengths longer than 
800 nm. Porphyrins, the most commonly used 
sensitizers, maximally absorb light of 400-410 nm 
- the Soret band, but also have minor absorption 
peaks at 630 nm (2, 3, 7).   
Discussion 
• Mechanism of action 
 The topically or systemically administered 
photosensitizer is activated by light of an adequate 
wavelength. The sensitizer absorbs the light and is 
transformed from its ground state into the excited 
singlet state, which is very unstable. Therefore, the 
drug can either emit fluorescence and go back to 
the ground state, or it can undergo electron spin 
conversion to its triplet state which is more stable. 
In the presence of oxygen, this molecule either 
reacts with a substrate and forms radicals (type I 
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reactions) or the energy is transferred to oxygen 
and forms reactive oxygen species (type II 
reaction).  As a result, the lipids, proteins and 
nucleic acids of targeted cells are altered and 
apoptosis occurs. The blood vessels are also 
affected and ischemia contributes to the death of 
cells (8-10). 
• Applications of photodynamic therapy in 
dermatology. PDT has several applications in 
dermatology, including neoplastic diseases, 
inflammatory diseases, microbial diseases, 
photoaging and rejuvenation (Table 1). While there 
is clear evidence on the effectiveness of PDT for 
actinic keratosis, BCC, especially the superficial 
type and Bowen's disease, the data regarding the 
use of PDT for other dermatological disorders is  
still scarce. However, studies show promising 
results (11-15). Contraindications to PDT are 
porphyria, systemic lupus erythematosus, non-
responsive tumors, allergy to the photosensitizing 
agent and photosensitive dermatoses (13).   
Adverse reactions 
Acute adverse reactions are photosensitivity, 
pain and inflammation. Photosensitivity depends 
on the administration route. Therefore, it is greater 
after systemic administration and it is localized 
after topical administration. Pain is the most 
common and redoubtable adverse effect. 
Inflammation manifesting as edema, induration, 
purpura and blistering can occur and can 
sometimes be serious, leading to tissue necrosis (1, 
11). Chronic adverse reactions are rare and include 
Type of lesion 
Strength of 
recommendation 
  
Neoplastic diseases 
 actinic keratoses 
 squamous cell carcinoma 
 basal cell carcinoma 
 Bowen's disease 
 cutaneous T cell lymphoma 
 extramammary Paget's disease 
Infectious diseases 
 viral warts 
 condyloma acuminata 
 cutaneous leishmaniasis 
 onychomycosis 
 
A 
D 
B 
A 
C 
C 
 
B 
B 
B 
N/A, case reports 
Inflammatory diseases 
 acne vulgaris 
 rosacea  
 hidradenitis suppurativa 
 morphea 
 psoriasis 
Cosmetic dermatology 
photorejuvenation  
  
 
B 
N/A 
N/A, case reports 
N/A, case reports 
D 
 
B  
 
Table 1. Applications of PDT in dermatology 
A - good evidence; B - fair evidence; C - poor evidence; D - fair evidence to support the rejection of the procedure; N/A 
not available 
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scarring, post inflammatory hypopigmentation and 
hyperpigmentation (1, 11). 
 Pain in photodynamic therapy 
 Pain is the most common side-effect 
associated with PDT and it is the most important 
factor that affects the patient's adherence to 
treatment. Most patients undergoing PDT 
experience some degree of pain, which can be 
mild, manifesting as stinging or burning, or more 
severe. It usually occurs during exposure, being 
most intense after a few minutes of irradiation, and 
decreases towards the end of the session. Few 
patients however also experience post-procedural 
pain. Therefore, some patients interrupt treatment 
sessions while others do not return for further 
treatments (11, 16, 17).  
 Most studies assessing pain during PDT 
use the visual analogue scale (VAS) for pain. The 
VAS for pain is a measurement instrument which 
tries to measure the amount of pain felt by the 
patient across a continuum ranging from none 
(marked as 0) to unbearable pain (marked as 10) 
(Figure 1).  The assessment of pain is subjective, 
the results depending on psychosocial factors and 
personal characteristics of the patient. According 
to some studies 20% of patients rate pain over six 
on the VAS (18, 19, 20).   
 A study performed by Sandberg et. al in 
2006 investigated pain related to ALA-PDT in 91 
patients treated for actinic keratosis. VAS was 
used for pain assessment. The authors found a 
mean value of VAS of 4.6. 21% of patients 
experienced severe pain (VAS 7-10) while 31% 
had little or no pain (VAS 0-3) (16).    
The mechanism of pain in PDT is still 
unknown. Aδ and C fibers are the major pain-
conducting nerve fiber systems. In PDT, pain is 
mainly mediated through the unmyelinated afferent 
C-fibers. C-fibers innervate polymodal receptors 
which respond to thermal, mechanical and 
chemical pain. The P substance and other 
neurotransmitters are also involved in PDT related 
pain. Hyperthermia, reactive oxygen species and 
inflammation have been discussed as possible 
triggers for pain in PDT. Nerve stimulation by 
ALA through Aδ and C fibers might also play a 
role (16).   
 Factors contributing to pain in PDT for 
dermatological disorders 
 Lesion type: actinic keratosis seem to be 
more painful than BCC and Bowen's disease. The 
treatment of acne lesions with PDT is also painful. 
A study performed by Schleyer et. al on 12 
patients with psoriasis treated with ALA-PDT 
showed unsatisfactory results, irradiation being 
interrupted several times due to pain and severe 
burning sensation. PDT for viral warts is also 
painful (11, 19, 21, 22).    
 Location: lesion located in well innervated 
areas such as the head, hands and perineum are 
more painful.  
Tampa M. et al. 
 Extent of lesions: larger lesions or more 
extensive treated areas are associated with more 
pain than small lesions (16, 17). 
 Type of photosensitizer: MAL and ALA are 
the most widely used photosensitizing agents in 
dermatology. Studies show that ALA-PDT is 
associated with more pain than MAL-PDT. A 
study performed by Gaal et. al in 2011, which 
included 87 patients with 182 lesions (AK, BCC 
and Bowen's disease) found that 21 of the 24 
treatments associated with intolerable pain that 
required treatment discontinuation were done with 
ALA-PDT (23). Wiegell et. al compared pain 
related to ALA-PDT with pain related to MAL-
PDT in 20 volunteers with tape-stripped normal 
skin. Patients were randomized to receive either 
ALA-PDT or MAL-PDT. The authors found that 
ALA-PDT was associated with more pain than 
MAL-PDT (24). Kasche et. al. performed a study 
on 69 patients with AK who received either ALA-
PDT or MAL-PDT. The authors found that 
treatment had to be interrupted in 54% of patients 
receiving ALA-PDT and 14% of patients receiving 
MAL-PDT (25). 
 One explanation might be that MAL is 
more lipophilic than ALA and penetrates tissues 
better. It also determines better accumulation of 
protoporphyrin IX in abnormal cells (19, 22). 
Another explanation could be that ALA and γ-
aminobutyric acid (GABA) have similar structures 
and are carried into cells by the same carrier 
systems, namely GABA-transporters. Therefore 
ALA might be transported into nerve endings by 
GABA receptors. GABA is the primary inhibitory 
neurotransmitter in the central nervous system and 
abnormal levels can determine neurological 
conditions and pain. The uptake of MAL on the 
other hand is cell dependent, MAL being 
transported by non-polar amino-acid transporters 
(19, 24, 26, 27). 
 Total dose of light and light intensity. Total 
dose of light, measured in joules/cm2 must be 
differentiated from the intensity of light, measured 
in watts/cm2. Higher total dose of light and higher 
light intensity both seem to be associated with 
higher levels of pain. Zeitouni et. al performed a 
retrospective review of pain control by a two-step 
irradiance schedule during ALA-PDT, in an 
existing dermatology data base. Their study 
included 14 patients who had initially received an 
irradiance of 30 or 50 mW/cm2 for 20 J/cm2 
followed by 150 mW/cm2 for 200-300 J/cm2. The 
author obtained a median VAS score of 1 and 
conlcuded that the two step irradiance protocole is 
effective in minimising pain (28).  The same group 
of researchers later performed a study on 21 
patients with 25 superficial BCCs who were 
treated with MAL-PDT. Patients were randomized 
to receive either laser with irradiance at 40 or 50 
mW/cm2 or LED with irradiance at 35 mW/cm2. 
After that all patients received irradiance at 70 
mW/cm2 for a total of 75 J/cm2. Pain was 
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measured using the VAS. The authors report that 
pain was minimal in the LED cohort (35/70 
mW/cm2), was mild in the 40/70 mW/cm2 laser 
cohort and was higher in the 50/70 mW/cm2 laser 
cohort (29). Radakovic et. al. performed a study on 
27 patients with at least 3 AKs on the face or scalp 
who were treated with ALA and irradiated with 70, 
100 or 140 j/cm2. The authors report no 
statistically significant difference between the 
three light doses regarding the degree of PDT-
induced pain (30). 
 Wavelength. Morton et. al compared ALA-
PDT with red light and green light in the treatment 
of Bowen's disease. The study included 61 
patients. The authors concluded that PDT with 
green light is less effective than PDT with red light 
in the treatment of Bowen's disease. However, the 
severity of the experienced pain was similar 
between the two cohorts, with red light being more 
painful than green light (22, 31).  
 Source of light. Several sources of light 
have been tried in order to increase efficacy and 
decrease pain. Babilas et. al performed a study on 
25 patients with AKs who received MAL-PDT  
and irradiation with LED on one side of the face 
and variable pulsed light (VPL) on the other side 
of the face. The authors showed that pain was 
significantly lower on the side treated with VPL 
(32). Kessels et. al compared PDT with LED with 
PDT with pulsed dye laser (PDL) in 61 patients 
with AK, the patients receiving LED-PDL on one 
side of the face and PDL-PDT on the other side. 
Pain was significantly lower in the PDL-PDT 
group. 78.7% of patients treated with PDL-PDT 
and 32.8 of patients in the LED group declared that 
they would undergo the treatment again (33). 
Some studies showed that daylight PDT is 
associated with less pain than conventional PDT. 
Wiegell et. al showed in a study performed on 29 
patients with AK, published in 2008, that LED-
PDT and daylight PDT have similar efficacy, 
LED-PDT being more painful than daylight-PDT 
(34). Braathen also conducted a study on 18 
patients with AKs who were treated with daylight -
PDT. Only one patients reported pain, scored as 5 
on the VAS (35).  
 Number of sessions. The second session of 
PD is more painful than the first one. 
 Skin phototype. Phototypes  and 2 are 
associated with more pain (19). 
 Pain management 
 Since pain is the most important side effect 
of PDT, several strategies for controlling pain have 
been researched. Until now no ideal method for 
pain management was found, probably because the 
precise mechanism of pain was not discovered 
(19).  
Topical anesthetics 
 Topical anesthetics have failed to prove 
their efficacy in controlling the pain associated 
with PDT. EMLA, an eutectic mixture of lidocaine 
2,5% and prilocaine 2.5%, is the most widely used 
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topical anesthetic. Langan et al performed a 
randomized, double blind study on 14 patients with 
AK treated with two sessions of ALA, who 
received EMLA on one session and placebo 
(Aqueous cream) on the other session. The authors 
report no difference between EMLA and placebo 
(36).  
 Tetracaine gel was also evaluated as a 
potential local anesthetic in PDT. Holmes et. al 
performed a prospective, double blind, placebo 
controlled study on 42 patients with non-
melanoma skin cancer who were randomized to 
receive either tetracaine gel or placebo gel. The 
pain in the tetracaine group was slightly lower than 
pain in the placebo group (VAS 4.0 vs. VAS 4.5). 
However, the difference was not statistically 
significant between the two groups (37). 
 Sandberg et. al tested the efficacy of 
capsaicin cream as a pain-reducing agent in 6 
patients with AKs who applied he cream 3-5 times 
a day for a week before treatment. The authors 
obtained no significant pain relief. However, all 
patients presented local adverse reactions (16).  
 Morphine gel also showed no efficacy in 
controlling PDT-related pain in a double-blind, 
placebo controlled study performed on 28 patients 
(27 AKs and 1 BCC) who were randomized to 
receive either morphine 0.3% gel or placebo 
cream. The authors reported identical maximum 
pain scores (5.5) and concluded that opioid 
receptors might not be involved in the mechanism 
of pain determined by PDT (38). Topical lidocaine 
cream associated with pretreatment with urea 40% 
to enhance lidocaine penetration also failed to 
prove its efficacy in reducing PDT -related pain 
(39).  
Locally injected anesthetics 
 Locally injected anesthetics and nerve 
block showed better results in reducing pain than 
topical anesthetics. Therefore, locally injected 
lidocaine, mepivacaine, ropovacaine, prilocaine 
and epinephrine all showed some good results in 
the management of PDT-related pain. Paoli et. al 
performed a study on 16 patients with AKs and 
used nerve block with mepivacaine and adrenaline 
on one side of the face and then performed PDT on 
both sides of the face. The authors report that the 
pain was significantly reduced on the anaesthetized 
side compared to the non-anesthetized side (40). 
Borelli et. al assessed the effect of subcutaneous 
infiltration anesthesia (SIA) on pain in PDT in 16 
patients who received SIA on one side of the face 
and oral analgesics only for the other side of the 
face and concluded that SIA decreases pain in PDT 
significantly more than oral analgesia (41).   
 Conscious sedation 
 Conscious sedation with inhaled 50% 
nitrous oxide/ oxygen has been recently reported in 
association with PDT and according to the authors, 
it could be an alternative for classical anesthetics 
(42, 43). 
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Transcutaneous electrical nerve stimulation (TENS)        
Halldin et. al performed a study on 14 patients 
with AKs who had previously experienced severe 
PDT-related pain. The electrodes for TENS were 
placed on the shoulders. Pain was assessed using 
the VAS. The authors observed a mean VAS of 
6.2, as compared to a mean VAS of 8.1 at baseline 
treatments and concluded that TENS could be an 
efficient pain-relieving technique (44). 
Other methods 
 Several other techniques were researched 
for decreasing PDT-related pain. Cooling of the 
treatment site seems to beneficial and is part of the 
treatment protocol in some centers. Cold air and 
cold water have both been used. Reducing 
irradiance, interruption of sessions and use of 
thermal water could also reduce pain in PDT (19, 
22, 45).    
 
Conclusion 
 PDT is a modern treatment with many 
applications in dermatology, but also other medical 
specialties. Pain is commonly experienced by 
patients undergoing PDT and is often associated 
with poor adherence to treatment. Several factors 
contribute to the occurrence of pain and many 
pain-relieving techniques have been studied in the 
attempt to alleviate it. However, since the exact 
mechanism is still unknown, most of those pain-
relieving strategies were unsuccessful. Further 
studies are therefore required.    
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